Download Full Text (507 KB)


Chronic myelogenous leukemia (CML) is a cancer described by uncontrolled proliferation of bone marrow cells that develop into the cells of the blood (Chen, 2014). In this study, the synergy of two drugs, bosutinib and a PF were tested for their efficacy in chemotherapy. Bosutinib is a kinase inhibitor that blocks phosphorylation of key proteins in the cell cycle of CML cells that allow them to proliferate (Boschelli et al., 2010). PF is an inhibitor of the Chk-1 protein that regulates many of the cell cycle checkpoints (Zhang et al., 2009). Two cell lines from CML were used in this experiment, BAF3/T315I and Adult/T315I. Both of these cell lines had the T315I mutation that provides resistance to the common CML chemotherapy drug imatinib (Gleevec). The cultured cells were treated with both bosutinib at 0.3 – 0.4 μM and PF at 1 – 1.2 μM individually as well as simultaneously. Results showed that the combined treatment of bosutinib and PF caused a large increase in cell apoptosis. These results show the possibility of a novel and effective chemotherapy combination for CML.

Publication Date


Subject Major(s)

Biomedical Engineering

Current Academic Year


Faculty Advisor/Mentor

Steven Grant


Virginia Commonwealth University. Undergraduate Research Opportunities Program

Is Part Of

VCU Undergraduate Research Posters


© The Author(s)

Synergy of Bosutinib and Chk-1 Inhibitor (PF) in Chemotherapy